EDMONTON, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 5, 2019 as per the following results:
| Nominee | Votes for | Votes withheld | % of votes cast |
| | | | FOR WITHELD |
| Glenn Rourke | 13,675,597 | 446,908 | 96.84% 3.16% |
| Donald J. Oborowsky | 13,675,397 | 447,108 | 96.83% 3.17% |
| John Zupancic | 13,575,397 | 547,108 | 96.13% 3.87% |
| Gilles Gagnon | 13,545,482 | 577,023 | 95.91% 4.09% |
| Dr. William Li | 13,675,597 | 446,908 | 96.84% 3.16% |
| Dr. Ulrich Kosciessa | 13,675,397 | 447,108 | 96.83% 3.17% |
All other matters at the Shareholders' meeting, namely the appointment of auditors, the re-approval and ratification of the Company’s Stock Option Plan, and the ratification of an amended and restated general operation by-law, as proposed in the Company’s information circular dated April 15, 2019, were also approved by shareholders.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 833-475-8247
E: czo@jtcir.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
